$ITCI
Intra-Cellular Therapies, Inc.

2016 Q4 Form 10-Q Financial Statement

#000119312516764370 Filed on November 09, 2016

View on sec.gov

Income Statement

Concept 2016 Q4 2016 Q3 2015 Q4
Revenue $97.90K $4.362K $30.66K
YoY Change 219.3% -53.45%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.950M $6.270M $6.540M
YoY Change 6.27% 61.18% 75.81%
% of Gross Profit
Research & Development $21.18M $23.92M $22.87M
YoY Change -7.39% -15.95% 96.48%
% of Gross Profit
Depreciation & Amortization $50.00K $50.00K $50.00K
YoY Change 0.0% 25.0% 400.0%
% of Gross Profit
Operating Expenses $28.13M $30.19M $29.40M
YoY Change -4.32% -6.68% 91.41%
Operating Profit -$30.18M
YoY Change -6.69%
Interest Expense $780.0K $12.26K $540.0K
YoY Change 44.44% -93.55% 440.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$27.25M -$29.43M -$28.83M
YoY Change -5.48% -8.48% 89.67%
Income Tax $230.0K $832.6K $0.00
% Of Pretax Income
Net Earnings -$27.49M -$30.27M -$28.83M
YoY Change -4.68% -5.89% 89.71%
Net Earnings / Revenue -28076.04% -693840.6% -94049.11%
Basic Earnings Per Share
Diluted Earnings Per Share -$635.3K -$699.9K -$668.4K
COMMON SHARES
Basic Shares Outstanding 43.27M shares 43.25M shares 43.02M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q4 2016 Q3 2015 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $384.1M $537.8M $475.2M
YoY Change -19.17% 5.31% 266.67%
Cash & Equivalents $48.64M $200.4M $47.16M
Short-Term Investments $335.5M $337.4M $428.0M
Other Short-Term Assets $4.000M $4.000M $8.000M
YoY Change -50.0% 166.67% 515.38%
Inventory
Prepaid Expenses
Receivables $94.34K $1.309K $30.66K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $388.2M $541.8M $483.3M
YoY Change -19.67% 5.77% 268.94%
LONG-TERM ASSETS
Property, Plant & Equipment $627.6K $677.7K $775.5K
YoY Change -19.07% -13.73% 1321.59%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $75.77K $75.77K $71.88K
YoY Change 5.41% 5.41% 1.31%
Total Long-Term Assets $703.4K $753.5K $847.4K
YoY Change -17.0% -12.12% 575.23%
TOTAL ASSETS
Total Short-Term Assets $388.2M $541.8M $483.3M
Total Long-Term Assets $703.4K $753.5K $847.4K
Total Assets $388.9M $542.6M $484.1M
YoY Change -19.67% 5.74% 269.23%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.755M $5.417M $1.633M
YoY Change 129.94% 668.39% -20.45%
Accrued Expenses $6.800M $10.30M $4.600M
YoY Change 47.83% 6.19% -45.88%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $125.0M $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $10.53M $140.7M $6.264M
YoY Change 68.15% 1254.48% -40.67%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $2.900M $2.600M $1.600M
YoY Change 81.25% 188.89%
Total Long-Term Liabilities $2.869M $2.564M $1.597M
YoY Change 79.61% 184.87%
TOTAL LIABILITIES
Total Short-Term Liabilities $10.53M $140.7M $6.264M
Total Long-Term Liabilities $2.869M $2.564M $1.597M
Total Liabilities $13.40M $143.3M $7.861M
YoY Change 70.48% 1171.32% -25.54%
SHAREHOLDERS EQUITY
Retained Earnings -$309.5M -$282.0M -$193.0M
YoY Change 60.31% 71.72% 118.74%
Common Stock $685.3M $681.5M $669.9M
YoY Change 2.3% 2.31% 220.65%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $375.5M $399.3M $476.2M
YoY Change
Total Liabilities & Shareholders Equity $388.9M $542.6M $484.1M
YoY Change -19.67% 5.74% 269.23%

Cashflow Statement

Concept 2016 Q4 2016 Q3 2015 Q4
OPERATING ACTIVITIES
Net Income -$27.49M -$30.27M -$28.83M
YoY Change -4.68% -5.89% 89.71%
Depreciation, Depletion And Amortization $50.00K $50.00K $50.00K
YoY Change 0.0% 25.0% 400.0%
Cash From Operating Activities -$28.45M -$29.66M -$35.06M
YoY Change -18.85% 44.61% 464.57%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$10.00K -$40.00K
YoY Change -100.0% -90.91%
Acquisitions
YoY Change
Other Investing Activities $1.680M $52.97M -$250.9M
YoY Change -100.67% -216.47% 17323.61%
Cash From Investing Activities $1.670M $52.97M -$250.9M
YoY Change -100.67% -216.21% 17326.39%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -125.0M 125.1M 320.0K
YoY Change -39153.13% -61.8% 357.14%
NET CHANGE
Cash From Operating Activities -28.45M -29.66M -35.06M
Cash From Investing Activities 1.670M 52.97M -250.9M
Cash From Financing Activities -125.0M 125.1M 320.0K
Net Change In Cash -151.8M 148.4M -285.7M
YoY Change -46.88% -43.23% 3668.87%
FREE CASH FLOW
Cash From Operating Activities -$28.45M -$29.66M -$35.06M
Capital Expenditures $0.00 -$10.00K -$40.00K
Free Cash Flow -$28.45M -$29.65M -$35.02M
YoY Change -18.76% 45.34% 463.93%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
43268243 shares
CY2015Q1 itci Net Proceeds From Public Offering
NetProceedsFromPublicOffering
121800000
CY2015Q3 us-gaap Share Price
SharePrice
43.50
CY2015Q3 itci Net Proceeds From Public Offering
NetProceedsFromPublicOffering
327400000
CY2015Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
332828289
CY2016Q3 us-gaap Available For Sale Securities Noncurrent
AvailableForSaleSecuritiesNoncurrent
0
CY2016Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2016Q3 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
218000
CY2016Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2498681
CY2016Q3 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
353392000
CY2016Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
43268243 shares
CY2016Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
43268243 shares
CY2016Q3 us-gaap Assets
Assets
542571982
CY2016Q3 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
47000
CY2016Q3 us-gaap Assets Current
AssetsCurrent
541818514
CY2016Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2016Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
3402792
CY2016Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
681475390
CY2016Q3 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
337577000
CY2016Q3 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
337405780
CY2016Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
200388020
CY2016Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1309
CY2016Q3 us-gaap Common Stock Value
CommonStockValue
4327
CY2016Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
4800000 shares
CY2016Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
5417451
CY2016Q3 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
2752381
CY2016Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
7520073
CY2016Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-171122
CY2016Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
2563809
CY2016Q3 us-gaap Liabilities
Liabilities
143253714
CY2016Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
542571982
CY2016Q3 us-gaap Liabilities Current
LiabilitiesCurrent
140689905
CY2016Q3 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
16000000
CY2016Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
75765
CY2016Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
677703
CY2016Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3176384
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
11.74
CY2016Q3 us-gaap Stockholders Equity
StockholdersEquity
399318268
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
19.53
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1836573 shares
CY2016Q3 us-gaap Secured Debt Current
SecuredDebtCurrent
125000000
CY2016Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-281990327
CY2016Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4023405
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
3110927 shares
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
19.53
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3110927 shares
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
61325044
CY2015Q4 us-gaap Available For Sale Securities Noncurrent
AvailableForSaleSecuritiesNoncurrent
9200000
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2015Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
592000
CY2015Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2356838
CY2015Q4 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
459155000
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
43155875 shares
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
43155875 shares
CY2015Q4 us-gaap Assets
Assets
484103528
CY2015Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1000
CY2015Q4 us-gaap Assets Current
AssetsCurrent
483256131
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2015Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
669878103
CY2015Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
428632000
CY2015Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
428041021
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
47159303
CY2015Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
30660
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
4316
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1632905
CY2015Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
1207143
CY2015Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
3423464
CY2015Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-590410
CY2015Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
1597105
CY2015Q4 us-gaap Liabilities
Liabilities
7860617
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
484103528
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6263512
CY2015Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
31100000
CY2015Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
71875
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
775522
CY2015Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3132360
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
476242911
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
13.72
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-193049098
CY2015Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8025147
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2737657 shares
CY2015Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
129900000
CY2015Q1 itci Share Issued During Period Shares Underwriters New Issues
ShareIssuedDuringPeriodSharesUnderwritersNewIssues
661481 shares
CY2015Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
345200000
CY2015Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
7935000 shares
CY2015Q3 itci Share Issued During Period Shares Underwriters New Issues
ShareIssuedDuringPeriodSharesUnderwritersNewIssues
1035000 shares
CY2016Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
350000000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-520328
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
271503245
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.25
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11649169
us-gaap Depreciation
Depreciation
92594
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-75873366
us-gaap Excess Tax Benefit From Share Based Compensation Operating Activities
ExcessTaxBenefitFromShareBasedCompensationOperatingActivities
0
us-gaap Revenues
Revenues
60705
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
136984
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
231146274
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1177654
us-gaap Operating Expenses
OperatingExpenses
76501745
us-gaap Net Income Loss
NetIncomeLoss
-75958625
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-75958625
us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
881143
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-110841675
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
85259
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
121128184
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-51603
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1347722
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
244886
us-gaap Operating Income Loss
OperatingIncomeLoss
-76441040
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
449569252
us-gaap Investment Income Interest
InvestmentIncomeInterest
482415
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-67224332
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
823585
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
449996887
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
64852576
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
317508
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.80 pure
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
745143
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.018 pure
us-gaap Share Based Compensation
ShareBasedCompensation
7466595
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y3M18D
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
33716032 shares
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-420275
dei Entity Registrant Name
EntityRegistrantName
Intra-Cellular Therapies, Inc.
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0001567514
dei Document Period End Date
DocumentPeriodEndDate
2016-09-30
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
153228717
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.06
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
17806565
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Concentration of Credit Risk</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> Cash equivalents are held with major financial institutions in the United States. Certificates of deposit held with banks may exceed the amount of insurance provided on such deposits. Generally, these deposits may be redeemed upon demand and, therefore, bear minimal risk.</p> </div>
us-gaap Revenues
Revenues
232807
us-gaap Depreciation
Depreciation
146784
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-88521941
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
us-gaap Excess Tax Benefit From Share Based Compensation Operating Activities
ExcessTaxBenefitFromShareBasedCompensationOperatingActivities
0
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
171059
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
320098309
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
5641847
us-gaap Operating Expenses
OperatingExpenses
90459085
us-gaap Net Income Loss
NetIncomeLoss
-88941229
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-88108611
us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
966704
us-gaap Interest Expense
InterestExpense
12260
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
90585289
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
419288
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
410732563
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-29351
us-gaap Line Of Credit Facility Expiration Date1
LineOfCreditFacilityExpirationDate1
2016-10-06
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3784546
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-3997852
us-gaap Operating Income Loss
OperatingIncomeLoss
-90226278
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
125450308
us-gaap Investment Income Interest
InvestmentIncomeInterest
2129927
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
832618
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-62806880
us-gaap Proceeds From Secured Lines Of Credit
ProceedsFromSecuredLinesOfCredit
125000000
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Use of Estimates</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Although actual results could differ from those estimates, management does not believe that such differences would be material.</p> </div>
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
48965
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
104995 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y4M24D
CY2015Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.91
CY2015Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3891744
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
49.47
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y8M12D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
0 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
4.29
dei Trading Symbol
TradingSymbol
ITCI
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
72652520
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
450308
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.80 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.017 pure
us-gaap Share Based Compensation
ShareBasedCompensation
10975931
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y10M24D
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
43229087 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Requisite Service Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
P3Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
478265 shares
itci Maturity Period Of Liquid Investments To Be Considered As Cash Equivalents
MaturityPeriodOfLiquidInvestmentsToBeConsideredAsCashEquivalents
Three months or less
itci Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Remaining Contractual Term2
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm2
P5Y10M24D
itci Share Based Compensation Arrangement By Share Based Payment Award Canceled Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardCanceledWeightedAverageRemainingContractualTerm
P0Y
itci Available For Sale Securities Maturity Period
AvailableForSaleSecuritiesMaturityPeriod
More than three months
itci Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageRemainingContractualTerm
P3Y8M12D
CY2015 us-gaap Available For Sale Securities Gross Unrealized Loss
AvailableForSaleSecuritiesGrossUnrealizedLoss
19000
CY2015 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y7M6D
CY2015Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-32127180
CY2015Q3 us-gaap Operating Expenses
OperatingExpenses
32349375
CY2015Q3 us-gaap Net Income Loss
NetIncomeLoss
-32160483
CY2016Q3 us-gaap Share Based Compensation
ShareBasedCompensation
3686746
CY2016Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
43253429 shares
CY2015Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-32160483
CY2015Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
33303
CY2015Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-32349375
CY2015Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
188892
CY2015Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
28457631
CY2015Q3 us-gaap Share Based Compensation
ShareBasedCompensation
2865990
CY2015Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
35320046 shares
CY2016Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.70
CY2016Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6270528
CY2016Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-30496262
CY2016Q3 us-gaap Revenues
Revenues
4362
CY2016Q3 us-gaap Operating Expenses
OperatingExpenses
30188760
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
-30265327
CY2016Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-29432709
CY2016Q3 us-gaap Interest Expense
InterestExpense
12260
CY2016Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-230935
CY2016Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-30184398
CY2016Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
763949
CY2016Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
832618
CY2016Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
23918232

Files In Submission

Name View Source Status
0001193125-16-764370-index-headers.html Edgar Link pending
0001193125-16-764370-index.html Edgar Link pending
0001193125-16-764370.txt Edgar Link pending
0001193125-16-764370-xbrl.zip Edgar Link pending
d247783d10q.htm Edgar Link pending
d247783dex101.htm Edgar Link pending
d247783dex102.htm Edgar Link pending
d247783dex103.htm Edgar Link pending
d247783dex311.htm Edgar Link pending
d247783dex312.htm Edgar Link pending
d247783dex32.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
itci-20160930.xml Edgar Link completed
itci-20160930.xsd Edgar Link pending
itci-20160930_cal.xml Edgar Link unprocessable
itci-20160930_def.xml Edgar Link unprocessable
itci-20160930_lab.xml Edgar Link unprocessable
itci-20160930_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending